NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

8621	Companies
142924	Keywords
78686	Articles
76378	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 01/29/2024 at 12:30, 1 year 2 months ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV

NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
PRESS RELEASE

published on 01/04/2024 at 12:30, 1 year 3 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco
NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections.

NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE

published on 11/28/2023 at 12:40, 1 year 4 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE

published on 11/15/2023 at 12:45, 1 year 5 months ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE

published on 11/14/2023 at 12:45, 1 year 5 months ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE

published on 10/16/2023 at 12:45, 1 year 6 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE

published on 10/12/2023 at 12:45, 1 year 6 months ago

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE

published on 08/21/2023 at 12:45, 1 year 8 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE

published on 07/11/2023 at 12:45, 1 year 9 months ago

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE

published on 07/06/2023 at 12:45, 1 year 9 months ago

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

Accesswire

Published on 04/21/2025 at 23:00, 55 minutes ago

Revolve to Present at the Planet MicroCap Showcase
Published on 04/21/2025 at 22:30, 1 hour 25 minutes ago

Zimtu Capital Corp. Announces Proposed Share Consolidation
Published on 04/21/2025 at 21:45, 2 hours 10 minutes ago

Stillwater Critical Minerals Announces Grant of Long-Term Performance Incentives and Restricted Share Units
Published on 04/21/2025 at 20:45, 3 hours 10 minutes ago

NV Gold Announces Shares for Debt Transaction
Published on 04/21/2025 at 18:20, 5 hours 35 minutes ago

NioCorp Announces Closing of Underwritten Public Offering, Including Partial Exercise of Underwriter's Option, for Total Gross Proceeds of Approximately $20.8 Million

View all ACCESSWIRE

EQS Group

Published on 04/21/2025 at 20:32, 3 hours 23 minutes ago

Freelance.com: résultats de l'année 2024
Published on 04/21/2025 at 17:48, 6 hours 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 04/21/2025 at 17:48, 6 hours 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 04/21/2025 at 17:47, 6 hours 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc
Published on 04/21/2025 at 17:46, 6 hours 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Urban Logistics REIT plc

Les Echos

Published on 04/18/2025 at 17:45, 3 days 6 hours ago

Saint-Gobain once again featured on CDP’s “Climate A List”
Published on 04/18/2025 at 17:45, 3 days 6 hours ago

Saint-Gobain figure une nouvelle fois sur la « Climate A List » établie par le CDP
Published on 04/18/2025 at 11:16, 3 days 12 hours ago

Déclaration hebdomadaire d'opérations effectuées du 14 au 17 avril 2025
Published on 04/18/2025 at 11:16, 3 days 12 hours ago

Disclosure of transactions in own shares from April 14 to April 17, 2025
Published on 04/18/2025 at 07:00, 3 days 16 hours ago

Uitnodiging voor de Jaarvergadering en Buitengewone Algemene Vergadering van aandeelhouders

View all LES ECHOS COMFI WIRE